Biomerica Inc. (BMRA)
BMRA trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-05-31, https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/0001493152-26-040851-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-05-31.
Profile
| Field | Value |
|---|---|
| Ticker | BMRA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000073290 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $4.5M |
| Net income | -$3.8M |
| Operating income | -$5.3M |
| Net margin | -84.8% |
| Operating margin | -119.5% |
| Revenue growth | -16.2% |
| Cash | $1.3M |
| Total assets | $6.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about our ability to continue as a going concern within twelve months following the issuance date of these financial statements." | 10-Q 2026-10-15 |
| Cash and burn | $2.7M cash; operating cash flow -$989K a quarter. | Report 2026-08-31 |
| Shares outstanding | 4,598,968 (2026-10-15); 2,869,900 a year earlier; 16,821,646 three years earlier. 3y figure adjusted for splits (1-for-8 overall). | Cover page 2026-10-15 |
| Reverse splits, 3 years | 1; latest 1-for-8 on 2025-04-21 | Source 2025-04-21 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-09-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Haskell & White LLP, Irvine, California, United States | PCAOB Form AP 2026-09-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $158K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-08-31 | $1.3M | -$1.2M | -$802K | $2.7M | No debt tags | $4.3M | 10-Q 2026-10-15 |
| Q4 2026 2026-05-31 | $875K | -$1.1M | -$912K | $1.3M | No debt tags | $4.5M | 10-K 2026-08-31 |
| Q3 2026 2026-02-28 | $987K | -$1.3M | -$1.3M | $1.3M | No debt tags | $4.3M | 10-Q 2026-04-13 |
| Q2 2026 2025-11-30 | $1.2M | -$1.3M | -$991K | $2.5M | No debt tags | $4.5M | 10-Q 2026-01-14 |
| Q1 2026 2025-08-31 | $1.4M | $2K | -$268K | $3.1M | No debt tags | $4.9M | 10-Q 2026-10-15 |
| Q4 2025 2025-05-31 | $749K | -$1.5M | -$662K | $2.4M | No debt tags | $5.3M | 10-K 2026-08-31 |
| Q3 2025 2025-02-28 | $1.1M | -$1.2M | -$1.0M | $3.1M | No debt tags | $5.7M | 10-Q 2026-04-13 |
| Q2 2025 2024-11-30 | $1.6M | -$950K | -$791K | $2.4M | No debt tags | $5.6M | 10-Q 2026-01-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-09-24 |
| Latest annual report | 10-K/A | 2026-09-28 |
| Latest quarterly / interim | 10-Q | 2026-10-15 |
| Latest current report | 8-K | 2026-10-15 |
| Latest proxy | DEF 14A | 2026-10-16 |
Source: SEC EDGAR submissions feed, 605 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.5% |
| 1 month | -26.5% |
| 3 months | -16.0% |
| Year to date | -46.0% |
| 1 year | -45.6% |
| From 52-week high | -52.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings Inc. | $1.79 | -7.26% | $5.3M |
| VNRX | VolitionRX Limited | $0.1998 | -13.13% | $7.2M |
| TRIB | Trinity Biotech plc | $5.38 | -11.89% | $4.4M |
| QCLS | Q/C Technologies Inc. | $0.3210 | +4.80% | $2.6M |
| IMDX | Insight Molecular Diagnostics Inc. | $1.86 | -13.08% | $60.9M |
| VRAX | Virax Biolabs Group Limited | $0.4480 | -26.87% | $603K |
| ICCC | ImmuCell Corporation | $11.42 | +6.23% | $103.8M |
| TKNO | Alpha Teknova Inc. | $7.77 | -5.36% | $488.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier